PRESS RELEASE published on 02/11/2025 at 07:00, 1 year 2 months ago NORMA Group completes a challenging financial year 2024 with a stable level of profitability NORMA Group successfully concludes 2024 with stable profitability. Preliminary figures show sales of EUR 1.2 billion, adjusted EBIT at EUR 92.3 million, and strong cash flow. Divestment of Water Management business initiated Market Challenges Profitability 2024 Financial Results NORMA Group Divestment Process
PRESS RELEASE published on 02/11/2025 at 07:00, 1 year 2 months ago BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE BioVersys advances BV500 NTM program with continued support from CF AMR Syndicate, developing therapies for NTM lung disease in CF patients. Company focuses on antibacterial products against MDR bacteria BioVersys BV500 NTM Program CF AMR Syndicate NTM Lung Disease MDR Bacteria
PRESS RELEASE published on 02/11/2025 at 07:00, 1 year 2 months ago TUI Group: 10th consecutive quarter of Und. EBIT growth – Hotels, Cruises and TUI Musement driving improvement in FY25 Q1 TUI Group reports 10th consecutive quarter of underlying EBIT growth in FY25 Q1, driven by Hotels, Cruises, and TUI Musement. Q1 revenue up +13% to €4.9bn. Market + Airline segment shows 31% lower underlying EBIT due to investments for summer season Revenue Growth Underlying EBIT TUI Group FY25 Q1 Market + Airline
PRESS RELEASE published on 02/11/2025 at 07:00, 1 year 2 months ago Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 Relief Therapeutics obtains European Patent Office grant for RLF-TD011, securing patent protection for epidermolysis bullosa treatment. Company advances wound care solution Relief Therapeutics European Patent Office Epidermolysis Bullosa Wound Treatment RLD-TD011
REGULATED PRESS RELEASE published on 02/11/2025 at 07:00, 1 year 2 months ago Biophytis dévoile ses perspectives stratégiques de l’année 2025 Biophytis dévoile ses perspectives stratégiques pour l’année 2025, incluant le lancement de nouveaux programmes cliniques et des collaborations clés dans le domaine des maladies liées à l'âge Stratégie Biophytis Partenariats Développement Clinique Maladies Liées À L'âge
REGULATED PRESS RELEASE published on 02/11/2025 at 07:00, 1 year 2 months ago Biophytis unveils its outlook strategies for 2025 Biophytis unveils its strategic outlook for 2025, focusing on clinical development and commercialization plans for BIO101 (20-Hydroxyecdysone) in obesity and sarcopenia, with key partnerships and agreements Biophytis Clinical Development BIO101 Obesity Strategic Outlook
PRESS RELEASE published on 02/11/2025 at 06:58, 1 year 2 months ago Board member Christina Johansson passes away Emmi Group announces the passing of Board member Christina Johansson, a valued financial expert and Chairwoman of the Audit Committee Board Member Emmi Group Audit Committee Financial Expert Christina Johansson
PRESS RELEASE published on 02/11/2025 at 06:58, 1 year 2 months ago Décès de Christina Johansson, membre du Conseil d'administration Décès de Christina Johansson, membre du Conseil d'administration du groupe Emmi. Annonce officielle avec condoléances et hommage au travail accompli Conseil D'administration Décès Emmi Christina Johansson Condoléances
PRESS RELEASE published on 02/11/2025 at 06:57, 1 year 2 months ago ALSO enters US - First step: Cloud ALSO Holding AG expands into the US market with a focus on cloud solutions, leveraging the country's large economy and high cloud usage. The company aims to drive cloud migrations, enhance cybersecurity, and promote AI adoption Expansion US Market ALSO Holding AG Cloud Solutions IT Services
PRESS RELEASE published on 02/11/2025 at 01:00, 1 year 2 months ago Onco-Innovations' Licensed PNKP Inhibitor Technology Shown to Increase Sensitivity of Cancer Cells to Radiation in Animal Study Onco-Innovations Limited introduces exclusive PNKP inhibitors to enhance sensitivity of cancer cells to radiation, potentially revolutionizing targeted cancer treatments Colorectal Cancer Radiation Therapy PNKP Inhibitors Onco-Innovations Limited Cancer Cells
Published on 05/01/2026 at 07:35, 9 minutes ago Snipp Interactive Reports Financial Results for Q4 and Fiscal 2025; Announces Conference Call on May 5, 2026
Published on 05/01/2026 at 04:00, 3 hours 44 minutes ago Jericho Energy Ventures Announces Short Delay in Filing of 2025 Annual Financial Statements
Published on 05/01/2026 at 03:25, 4 hours 19 minutes ago McEwen Inc. and Golden Lake Exploration Inc. Announce Closing of Arrangement
Published on 05/01/2026 at 02:55, 4 hours 49 minutes ago GLG Life Tech Corporation Reports 2025 Annual & Fourth Quarter Financial Results
Published on 05/01/2026 at 01:00, 6 hours 44 minutes ago PPX Mining Announces Grant of Stock Options, Restricted Share Units and Deferred Share Units
Published on 04/30/2026 at 23:39, 8 hours 5 minutes ago Anemoi International Ltd: Final Results For Year Ended 31 December 2025
Published on 04/30/2026 at 22:35, 9 hours 9 minutes ago Curaleaf Completes Buyout of Remaining Stake in Germany's Four 20 Pharma
Published on 04/30/2026 at 22:04, 9 hours 40 minutes ago Interim individual financial statements for the period ending on March 31, 2026 of Sirma Group Holding JSC
Published on 04/30/2026 at 19:00, 12 hours 43 minutes ago DOUGLAS Group grows sales in Q2 and updates full-year guidance on adjusted EBITDA
Published on 04/30/2026 at 21:21, 10 hours 22 minutes ago CP -Mise à disposition du rapport financier annuel 2025
Published on 04/30/2026 at 20:00, 11 hours 43 minutes ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 20:00, 11 hours 43 minutes ago AMA Corp PLC : Résultats 2025 & Chiffre d'affaires du 1er trimestre 2026
Published on 04/30/2026 at 19:16, 12 hours 28 minutes ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:16, 12 hours 28 minutes ago AXA annonce les résultats de son Assemblée Générale